1. Global Allergy Forum and 3rd Davos Declaration 2015: Atopic dermatitis/Eczema: challenges and opportunities toward precision medicine. Issue 5 (8th March 2016) Authors: Bieber, T.; Akdis, C.; Lauener, R.; Traidl‐Hoffmann, C.; Schmid‐Grendelmeier, P.; Schäppi, G.; Allam, J.‐P.; Apfelbacher, C.; Augustin, M.; Beck, L.; Biedermann, T.; Braun‐Fahrländer, C.; Chew, F. T.; Clavel, T.; Crameri, R.; Darsow, U.; Deleuran, M.; Dittlein, D.; Duchna, H.‐W.; Eichenfeld, L. Journal: Allergy Issue: Volume 71:Issue 5(2016:May) Page Start: 588 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Report from the fourth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative). (19th July 2016) Authors: Chalmers, J.R.; Simpson, E.; Apfelbacher, C.J.; Thomas, K.S.; von Kobyletzki, L.; Schmitt, J.; Singh, J.A.; Svensson, Å.; Williams, H.C.; Abuabara, K.; Aoki, V.; Ardeleanu, M.; Awici‐Rasmussen, M.; Barbarot, S.; Berents, T.L.; Block, J.; Bragg, A.; Burton, T.; Bjerring Clemmensen, K.K.; Creswell‐... Journal: British journal of dermatology Issue: Volume 175:Number 1(2016) Page Start: 69 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Report from the fourth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative). (1st July 2016) Authors: Chalmers, J.R.; Simpson, E.; Apfelbacher, C.J.; Thomas, K.S.; von Kobyletzki, L.; Schmitt, J.; Singh, J.A.; Svensson, Å.; Williams, H.C.; Abuabara, K.; Aoki, V.; Ardeleanu, M.; Awici‐Rasmussen, M.; Barbarot, S.; Berents, T.L.; Block, J.; Bragg, A.; Burton, T.; Bjerring Clemmensen, K.K.; Creswell‐... Journal: British journal of dermatology Issue: Volume 175:Number 1(2016) Page Start: 69 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. The first trial of CIM331, a humanized antihuman interleukin‐31 receptor A antibody, in healthy volunteers and patients with atopic dermatitis to evaluate safety, tolerability and pharmacokinetics of a single dose in a randomized, double‐blind, placebo‐controlled study. (1st February 2016) Authors: Nemoto, O.; Furue, M.; Nakagawa, H.; Shiramoto, M.; Hanada, R.; Matsuki, S.; Imayama, S.; Kato, M.; Hasebe, I.; Taira, K.; Yamamoto, M.; Mihara, R.; Kabashima, K.; Ruzicka, T.; Hanifin, J.; Kumagai, Y. Journal: British journal of dermatology Issue: Volume 174:Number 2(2016) Page Start: 296 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. The first trial of CIM331, a humanized antihuman interleukin‐31 receptor A antibody, in healthy volunteers and patients with atopic dermatitis to evaluate safety, tolerability and pharmacokinetics of a single dose in a randomized, double‐blind, placebo‐controlled study3. (19th December 2015) Authors: Nemoto, O.; Furue, M.; Nakagawa, H.; Shiramoto, M.; Hanada, R.; Matsuki, S.; Imayama, S.; Kato, M.; Hasebe, I.; Taira, K.; Yamamoto, M.; Mihara, R.; Kabashima, K.; Ruzicka, T.; Hanifin, J.; Kumagai, Y. Journal: British journal of dermatology Issue: Volume 174:Number 2(2016) Page Start: 296 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗